Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide for Acute Kidney Injury
2023-508664-30-00Phase 3Authorised
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF) comparing Nicotinamide with Placebo (microcrystalline cellulose) (2 arms). Primary endpoint: Complete renal recovery rate at day 21. Planned start May 2025; status: authorised.
02
Drugs
nicotinamide
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2023-508664-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508664-30-00.